Evidence library · Cardiometabolic
Why blood pressure, lipids, weight distribution and insulin all move at once around menopause — and what genuinely moves the numbers back.
Each card is one claim with the source we read it in. The badge tells you what kind of evidence it is, a clinical guideline carries more weight than a narrative review for "what should I do" questions, while a mechanism paper is useful for "why does this happen". Click Read the source to go straight to the original. If a link breaks, please tell us, our admin link-checker watches these URLs.
Estrogen was quietly running cover for decades. As it drops, four things move at once: blood vessels stiffen and blood pressure rises, lipids drift the wrong way, fat redistributes to the middle, and cells stop listening to insulin as well. Most of it is silent, most of it is measurable, and most of it responds to known levers if it's caught early.
Vascular stiffness and blood pressure rise across the menopause transition independent of chronological age, with a distinct acceleration around the final menstrual period.
The mechanistic basis for 'why did my BP drift up when nothing else changed?'. A home cuff and a monthly reading is a reasonable response.
Read the sourceLDL cholesterol and triglycerides rise, and HDL particle quality shifts, across the menopause transition; the changes track the transition itself more closely than chronological age.
If your last lipid panel was pre-menopause, ask for a fresh one. What looked fine at 45 often doesn't at 52.
Read the sourceVisceral (central) adiposity increases across the menopause transition even when total body weight is stable, and visceral fat carries higher cardiometabolic risk than fat elsewhere.
Why the scale can lie. Waist circumference (halfway between lowest rib and hip bone) is the cheaper, honest measure.
Read the sourceInsulin sensitivity falls across perimenopause, with measurable rises in fasting glucose and HbA1c that often push previously-normal women into prediabetes.
The 'my numbers crept up and no one flagged it' phenomenon. Reversible in the prediabetes window; much harder once it becomes type 2.
Read the sourceMore women die of heart disease than of all cancers combined postmenopause. It's also the most under-screened-for risk in midlife women's health — often because the appointment agenda gets filled with vasomotor symptoms and the cardiometabolic conversation never happens. The AHA's own scientific statement is unambiguous about the size of the shift.
Cardiovascular risk markers accelerate across the menopause transition, and the transition itself (not chronological age alone) predicts increased CVD risk. Menopause is a distinct cardiovascular risk window that deserves proactive screening and intervention.
El Khoudary et al · American Heart Association
The single most-citable document if you're trying to get a doctor to take midlife cardiovascular screening seriously. Bring it.
Read the sourceAlmost every intervention with strong evidence for cardiometabolic risk in midlife women is either free (movement, sleep, food pattern) or a well-understood prescription (MHT started in the timing-hypothesis window, statins where appropriate). The gap is almost never 'we don't know what works' — it's 'nobody built time into the appointment to talk about it'.
The US Physical Activity Guidelines (aerobic activity plus twice-weekly muscle-strengthening) reduce all-cause and cardiovascular mortality, with additional benefits for glucose control, bone density, and body composition in midlife women.
The strength-training half is the one most consistently under-done by midlife women. Muscle is the biggest glucose disposal site you have.
Read the sourceA Mediterranean dietary pattern (olive oil, fish, vegetables, legumes, nuts, whole grains) reduces cardiovascular events in a primary-prevention population.
Estruch et al · n=7447
The single dietary pattern with the strongest primary-prevention evidence. Notably not a 'lose weight' intervention — the benefit held even without weight loss.
Read the sourceMenopausal hormone therapy started in women under 60 or within 10 years of menopause does not increase coronary heart disease risk and may modestly reduce all-cause mortality — the 'timing hypothesis'.
The evidence behind the modern 'start early, or don't start' framing. Individualised risk conversation, but the numbers are worth reading rather than trusting a headline.
Read the sourceThe evidence base for women who arrive at menopause already living with type 1 or type 2 diabetes is thin — and honestly named as such by the researchers working on it. The best current sources are the funded research programmes actively closing the gap. We link them here so you can see the shape of what's known (and what isn't), and take it to your diabetes team if your numbers have drifted.
Aerobic vs resistance exercise produce different blood glucose responses in menopausal women with type 1 diabetes, and existing exercise guidance was largely built on men and premenopausal women.
Actively-funded work rather than a completed trial. Named here because the clinical gap it addresses (women T1D navigating perimenopause) has almost no other evidence base to cite.
Read the sourceMenopausal sleep disruption and stress may compound cardiovascular risk in women with type 2 diabetes via the GLP-1 and GIP hormone pathways — the same pathways targeted by semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro).
Mechanistic hypothesis-generating work, not a clinical recommendation. Useful for the 'my sleep is wrecked AND my sugars are off AND my cardiovascular risk is climbing' conversation, which almost never gets connected in one appointment.
Read the sourceLatent autoimmune diabetes in adults (LADA) is slowly-developing type 1 diabetes that is commonly misdiagnosed as type 2 in midlife women; GAD antibody testing distinguishes them and changes the treatment pathway.
Adjacent but worth naming here. Same evidence card also appears on /evidence/autoimmune. If oral diabetes meds are working less well than expected, GAD antibodies + C-peptide is the conversation.
Read the source